Oric Pharmaceuticals
Lori Friedman currently serves as a Board member at NextRNA Therapeutics since September 2023 and has been the Chief Scientific Officer at ORIC Pharmaceuticals since July 2019. Prior to these roles, Lori Friedman held various positions at Genentech from July 2004 to July 2019, including Sr. Director of Translational Oncology and Director of Cancer Signaling and Translational Oncology. Lori Friedman also worked at Exelixis from March 1998 to June 2004, where roles included Director of Signal Transduction Research and Oncology Program Leader. Educational qualifications include a PhD in Molecular and Cell Biology from the University of California, Berkeley, and post-doctoral fellowships in Breast Cancer Genetics at both Cambridge University and the University of Washington, Seattle. Lori Friedman holds a B.S. in Microbiology from the University of Iowa.
This person is not in any offices
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.